Welcome to this subway-themed activity where you can choose different subway lines for the education that is the most relevant to you. Steven Feldman, MD, PhD, discusses some of the recent developments in the management of psoriasis, with a focus on the biologic therapies. He summarizes key points from the American Academy of Dermatology and National Psoriasis Foundation consensus guidelines for managing comorbid conditions, treatment targets, and the clinical application of biologics. Dr. Feldman adds his perspective on how to address patient concerns about the safety of biologic treatments and the increased risk of comorbidities patients with psoriasis may face.

Content Areas

  • Comorbidities in patients with psoriasis
  • Biologic treatments for psoriasis
  • Safety of biologic treatments for psoriasis
  • TNF-α inhibitors
  • IL-17 inhibitors
  • IL-23 inhibitors

Target Audience

The target learning audience is a national audience of dermatologists, dermatology physician assistants, nurse practitioners, and other clinicians who treat patients with moderate-to-severe psoriasis.


Steven Feldman, MD, PhD
Department of Dermatology
Wake Forest School of Medicine
Winston-Salem, North Carolina
Enter your information to begin.
CME Credit
Available Credit: 1.00 AMA PRA Category 1 Credit™.
Opens: September 30, 2019
Expires: September 30, 2020
Target Audience: Dermatologists
Primary Care Physicians
Nurse Practitioners
Physician Assistants
Other Healthcare Providers
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.